Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (PCROWD) PCROWD

What's the purpose of this trial?

The PCROWD, a tissue bank and clinical information repository, is an indispensable component of the research pipeline. Its main objective is to collect, process, and store tissue samples from patients with precursor blood conditions. Patients with such conditions have traditionally been told to "Watch and Wait" and have not had any treatment. The ability to follow these patients serially, i.e., at the same time they are followed clinically, will provide scientists with a rich source of samples and data.


The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease. Some of the blood cancer precursor conditions being studied as part of this protocol are monoclonal gammopathy of undetermined significance (MGUS), Smoldering Multiple Myeloma (SMM) or Smoldering Waldenström Macroglobulinemia, Early Myelodysplastic Syndrome (MDS), Monoclonal B-Cell Lymphocytosis, and Myeloproliferative Neoplasms (MPN).

Research scientists at Dana-Farber identified a great need to create a large database of clinical and epidemiological information from patients with precursor conditions. In response to this need, Dana-Farber established the CPOP in 2014. This first of its kind clinic focuses solely on the identification of precursor conditions in patients, and the gathering of clinical and epidemiological information that will continually fuel research aimed at identifying novel therapeutic options to prevent or delay eventual disease progression.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Patients with known or suspected precursor hematological conditions who have not had treatment which include the following subgroups of diseases are eligible to participate:

  • Early cases of Multiple Myeloma and Waldenström Macroglobulinemia (WM) such as monoclonal gammopathy of undetermined significance (MGUS), Smoldering Multiple Myeloma (SMM) or Smoldering Waldenström Macroglobulinemia
  • Early Myelodysplastic Syndrome (MDS)
  • Monoclonal B-Cell Lymphocytosis
  • Myeloproliferative Neoplasms (MPN), including patients treated with Hydroxyurea

Additional Trial Information

Observational Trial

Enrollment: 1,000 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Dana-Farber Cancer Institute (Main)

Boston, MA

Open and Accepting


West Michigan Cancer Center

Kalamazoo, MI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message